Bartlett & Co. LLC Lowers Stake in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

Bartlett & Co. LLC reduced its position in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Rating) by 90.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,000 shares of the company’s stock after selling 45,000 shares during the quarter. Bartlett & Co. LLC owned 0.05% of Checkpoint Therapeutics worth $26,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Morgan Jess S & Co. Inc. lifted its stake in Checkpoint Therapeutics by 66.6% in the 3rd quarter. Morgan Jess S & Co. Inc. now owns 1,894,694 shares of the company’s stock valued at $1,970,000 after buying an additional 757,372 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Checkpoint Therapeutics by 307.5% in the 1st quarter. Renaissance Technologies LLC now owns 923,035 shares of the company’s stock valued at $1,634,000 after buying an additional 696,535 shares in the last quarter. Spotlight Asset Group Inc. purchased a new position in Checkpoint Therapeutics in the 3rd quarter valued at about $622,000. PVG Asset Management Corp purchased a new position in Checkpoint Therapeutics in the 3rd quarter valued at about $408,000. Finally, Goldman Sachs Group Inc. purchased a new position in Checkpoint Therapeutics in the 1st quarter valued at about $292,000.

Insider Transactions at Checkpoint Therapeutics

In other news, CEO James F. Oliviero III sold 10,261 shares of the firm’s stock in a transaction that occurred on Wednesday, February 1st. The shares were sold at an average price of $4.77, for a total transaction of $48,944.97. Following the completion of the sale, the chief executive officer now owns 182,121 shares in the company, valued at approximately $868,717.17. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO James F. Oliviero III sold 5,548 shares of Checkpoint Therapeutics stock in a transaction that occurred on Monday, February 27th. The shares were sold at an average price of $4.65, for a total value of $25,798.20. Following the completion of the sale, the chief executive officer now owns 134,573 shares in the company, valued at approximately $625,764.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James F. Oliviero III sold 10,261 shares of Checkpoint Therapeutics stock in a transaction that occurred on Wednesday, February 1st. The shares were sold at an average price of $4.77, for a total transaction of $48,944.97. Following the completion of the sale, the chief executive officer now owns 182,121 shares of the company’s stock, valued at approximately $868,717.17. The disclosure for this sale can be found here. Insiders sold 35,626 shares of company stock worth $182,446 in the last 90 days. Insiders own 4.30% of the company’s stock.

Checkpoint Therapeutics Stock Performance

Shares of NASDAQ CKPT opened at $3.64 on Friday. The company has a 50 day simple moving average of $5.27 and a 200-day simple moving average of $3.04. Checkpoint Therapeutics, Inc. has a 1 year low of $3.52 and a 1 year high of $19.30.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CKPT. Lake Street Capital decreased their price target on shares of Checkpoint Therapeutics from $41.00 to $32.00 in a research note on Thursday, March 2nd. B. Riley raised their target price on shares of Checkpoint Therapeutics from $7.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, December 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $76.00 target price on shares of Checkpoint Therapeutics in a research note on Thursday, March 2nd.

Checkpoint Therapeutics Company Profile

(Get Rating)

Checkpoint Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.